Regenerative medicine meets translational oncology: Modeling leukemic bone marrow niche

Natalia Borbaran-Bravo¹, Patricia Arreba-Tutusaus¹, Malte U Ritter¹, Masoud Nasri¹, Maksim Klimiankou¹, Julia Skokowa²

Affiliations

¹ Division of Translational Oncology, Department of Oncology, Hematology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany.
² Division of Translational Oncology, Department of Oncology, Hematology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany. Electronic address: julia.skokowa@med.uni-tuebingen.de.

PMID: 35977470
PMCID: PMC9418842
DOI: 10.1016/j.xcrm.2022.100724

Regenerative medicine meets translational oncology: Modeling leukemic bone marrow niche

Natalia Borbaran-Bravo et al. Cell Rep Med. 2022.

. 2022 Aug 16;3(8):100724.

doi: 10.1016/j.xcrm.2022.100724.

Authors

Natalia Borbaran-Bravo¹, Patricia Arreba-Tutusaus¹, Malte U Ritter¹, Masoud Nasri¹, Maksim Klimiankou¹, Julia Skokowa²

Affiliations

¹ Division of Translational Oncology, Department of Oncology, Hematology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany.
² Division of Translational Oncology, Department of Oncology, Hematology, Clinical Immunology and Rheumatology, University Hospital Tuebingen, Tübingen, Germany. Electronic address: julia.skokowa@med.uni-tuebingen.de.

PMID: 35977470
PMCID: PMC9418842
DOI: 10.1016/j.xcrm.2022.100724

Abstract

Most studies on leukemia focus on leukemia cells as isolated objects without considering the bone marrow niche. Pal et al. have recreated the bone marrow niche using induced pluripotent stem cells (iPSCs), identifying CDH2 as a therapeutically druggable leukemia-promoting factor.¹.

PubMed Disclaimer

Conflict of interest statement

Declaration of interests The authors declare no competing interests.

Figures

**Figure 1**
Leukemia cell interaction with bone marrow niche components via N-cadherin causes therapy resistance Image created with BioRender.com.

See this image and copyright information in PMC

Cited by

Exploring the promising potential of induced pluripotent stem cells in cancer research and therapy.
Chehelgerdi M, Behdarvand Dehkordi F, Chehelgerdi M, Kabiri H, Salehian-Dehkordi H, Abdolvand M, Salmanizadeh S, Rashidi M, Niazmand A, Ahmadi S, Feizbakhshan S, Kabiri S, Vatandoost N, Ranjbarnejad T. Chehelgerdi M, et al. Mol Cancer. 2023 Nov 28;22(1):189. doi: 10.1186/s12943-023-01873-0. Mol Cancer. 2023. PMID: 38017433 Free PMC article. Review.
A human mesenchymal spheroid prototype to replace moderate severity animal procedures in leukaemia drug testing.
Wilson A, Hockney S, Parker J, Angel S, Blair H, Pal D. Wilson A, et al. F1000Res. 2023 Nov 6;11:1280. doi: 10.12688/f1000research.123084.2. eCollection 2022. F1000Res. 2023. PMID: 38046539 Free PMC article.
Targeting N-cadherin (CDH2) and the malignant bone marrow microenvironment in acute leukaemia.
Parker J, Hockney S, Blaschuk OW, Pal D. Parker J, et al. Expert Rev Mol Med. 2023 May 3;25:e16. doi: 10.1017/erm.2023.13. Expert Rev Mol Med. 2023. PMID: 37132370 Free PMC article. Review.
Artificial intelligence powers regenerative medicine into predictive realm.
Garmany A, Terzic A. Garmany A, et al. Regen Med. 2024 Dec;19(12):611-616. doi: 10.1080/17460751.2024.2437281. Epub 2024 Dec 11. Regen Med. 2024. PMID: 39660914 Free PMC article. Review.

References

1. Pal D., Blair H., Parker J., Hockney S., Beckett M., Singh M., Tirtakusuma R., Nelson R., McNeill H., Angel S., et al. hiPSC-derived bone marrow milieu identifies a clinically actionable driver of niche-mediated treatment resistance in leukaemia. Cell Reports Medicine. 2022;3 100724-1–100724–18.e8. - PMC - PubMed
1. Takahashi K., Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676. doi: 10.1016/j.cell.2006.07.024. - DOI - PubMed
1. Alimperti S., Andreadis S.T. CDH2 and CDH11 act as regulators of stem cell fate decisions. Stem Cell Res. 2015;14:270–282. doi: 10.1016/j.scr.2015.02.002. - DOI - PMC - PubMed
1. Blaschuk O.W. Potential therapeutic Applications of N-cadherin antagonists and Agonists. Front. Cell Dev. Biol. 2022;10:866200. doi: 10.3389/fcell.2022.866200. - DOI - PMC - PubMed
1. Cavallaro U., Dejana E. Adhesion molecule signalling: not always a sticky business. Nat. Rev. Mol. Cell Biol. 2011;12:189–197. doi: 10.1038/nrm3068. - DOI - PubMed

MeSH terms

Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information
Research Materials
- NCI CPTC Antibody Characterization Program

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Regenerative medicine meets translational oncology: Modeling leukemic bone marrow niche

Affiliations

Regenerative medicine meets translational oncology: Modeling leukemic bone marrow niche

Authors

Affiliations

Abstract

Conflict of interest statement

Figures

Similar articles

Cited by

References

MeSH terms

LinkOut - more resources

Full Text Sources

Medical

Research Materials